Economics of Oncology Drug Development
Transcript of Economics of Oncology Drug Development
![Page 1: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/1.jpg)
Unresolved Issues in the Unresolved Issues in the Globalization of Clinical TrialsGlobalization of Clinical Trials
Robert M Califf MDRobert M Califf MD
Vice Chancellor for Clinical ResearchVice Chancellor for Clinical Research
![Page 2: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/2.jpg)
Globalization of Clinical TrialsGlobalization of Clinical Trials
Current State Current State MoneyMoney
EthicsEthics
Cultural environmentCultural environment
Genetic variationGenetic variation
Envisioning a positive futureEnvisioning a positive future
![Page 3: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/3.jpg)
• Since 2002, the number of FDA investigators outside the US has grown by 15% annually, while the number inside the US has declined by 5.5%.
• One-third of phase 3 trials of the 20 largest US pharmaceutical companies are being conducted solely outside the US.
• For those same firms and studies, a majority of study sites (13,521 of 24,206) are outside the US.
Source: Glickman, SW et al. NEJM 2009
![Page 4: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/4.jpg)
The Globalization of Clinical Investigators
80% 77%70%
62% 57%
9% 10%11%
13%14%
5% 12% 13%19% 25% 29%
86%
9%
0%
25%
50%
75%
100%
1997 1999 2001 2003 2005 2007P
US-Based Western Europe Rest of WorldPercent of Total1572s Filed
Sources: Tufts CSDD
![Page 5: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/5.jpg)
Growth in Numbers of ActiveFDA-Regulated Investigators
2001 2003 2006 5-yr Growth Rate
Most Recent 3-yr Growth
Rate
Russia 176 317 623 28.8% 25.3%
Poland 215 314 322 8.4% .8%
Brazil 139 296 292 16% -.5%
Costa Rica 12 20 22 12.9% 3.2%
Argentina 174 305 462 21.6% 14.8%
China 80 120 307 30.9% 36.8%
India 64 145 464 48.6% 47.4%
Sources: Tufts CSDD
![Page 6: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/6.jpg)
The test of a first-rate intelligence is The test of a first-rate intelligence is the ability to hold two opposed ideas in the ability to hold two opposed ideas in the mind at the same time, and still the mind at the same time, and still retain the ability to function.retain the ability to function.
F. Scott FitzgeraldF. Scott Fitzgerald, , "The Crack-Up" (1936)"The Crack-Up" (1936)US novelist (1896 - 1940)US novelist (1896 - 1940)
![Page 7: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/7.jpg)
Creative TensionCreative Tension Globalization of clinical research is a very good Globalization of clinical research is a very good
thing for the US and for all of us in a flat worldthing for the US and for all of us in a flat worldWe need more evidence to guide effective practice We need more evidence to guide effective practice in the USin the US
So does every other country in the worldSo does every other country in the world
Driving globalization because of poor efficiency Driving globalization because of poor efficiency in the conduct of research in the US is a bad in the conduct of research in the US is a bad thing for the USthing for the US
By the way, the same thinking could be applied to By the way, the same thinking could be applied to any economically advantaged country that begins to any economically advantaged country that begins to think it is “above it all”think it is “above it all”
![Page 8: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/8.jpg)
Dollars and Sense: Factors Pushing Dollars and Sense: Factors Pushing Clinical Research Out of the U.S.Clinical Research Out of the U.S.
Kevin Schulman, MDDirector, Health Sector Management Program
The Fuqua School of Business
Director, Center for Clinical and Genetic EconomicsDuke University Medical Center
American Federation for Medical Research (AFMR)
April 14, 2009
![Page 9: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/9.jpg)
Globalization of Clinical Trials—The GoodGlobalization of Clinical Trials—The Good Larger sample sizes are neededLarger sample sizes are needed
Modest treatment effects predominateModest treatment effects predominate
Subgroups must be validatedSubgroups must be validated
Will become even more important in “personalized” or Will become even more important in “personalized” or “stratified” medicine“stratified” medicine
Competition spurs improvementCompetition spurs improvement
More research will be doneMore research will be done
Collaboration leads to shared learningCollaboration leads to shared learningPractice patternsPractice patterns
EthicsEthics
Will ensure transparency on results reportingWill ensure transparency on results reporting
Adequate sample sizes/study designs to understand genetic Adequate sample sizes/study designs to understand genetic heterogeneityheterogeneity
![Page 10: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/10.jpg)
Globalization: A NecessityGlobalization: A Necessity
Proof of concept trials—there are Proof of concept trials—there are pharmacogenomic differencespharmacogenomic differences
Efficacy trials—the context of clinical practice Efficacy trials—the context of clinical practice mattersmatters
Effectiveness trials—the relative costs and Effectiveness trials—the relative costs and balance of risk and benefits are context balance of risk and benefits are context dependentdependent
The question is not whether we globalize, it is The question is not whether we globalize, it is why we do it, how we handle cultural why we do it, how we handle cultural differences and how we lump or split findings differences and how we lump or split findings
![Page 11: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/11.jpg)
Economic Proposition to Industry From Economic Proposition to Industry From GlobalizationGlobalization
Return
0
$
$800 – $880 mil (2001)
$1 – $10 billion*
PatentPatent LaunchLaunchPatentPatent
ExpirationExpiration
Pre-LaunchPre-Launch
fall-off*fall-off*speed*speed*
duration*duration*
maximize area*maximize area*
Decrease costs or time
Potential local market opportunity
No requirement to match study populations to
target marketsROI
![Page 12: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/12.jpg)
The Good– the US Needs to Wake Up!The Good– the US Needs to Wake Up! Rapid movement to moving clinical trials away Rapid movement to moving clinical trials away
from USfrom US
US is inferior in:US is inferior in:Study cost indexStudy cost index
Population indicators (tx naïve patients)Population indicators (tx naïve patients)
Business environmentBusiness environment
US is better, but losing ground quickly in:US is better, but losing ground quickly in:Clinical research personnel qualificationClinical research personnel qualification
Study site organizationStudy site organization
Thought leader quantityThought leader quantity
![Page 13: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/13.jpg)
Image Source: http://www.pandora.ca/pictures21/900666.jpg
![Page 14: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/14.jpg)
The Demise of EmpiresThe Demise of Empires Dominance at a point in timeDominance at a point in time
Arrogance about superiorityArrogance about superiority
Failure to pay attention to quality of workFailure to pay attention to quality of work
Leaders content to “ride the wave”Leaders content to “ride the wave”
Entrenched interests can buy stability through Entrenched interests can buy stability through controlling laws and regulationscontrolling laws and regulations
Inability to create or respond to innovationInability to create or respond to innovation
Cost of transactions exceeds cost of actually Cost of transactions exceeds cost of actually doing the work!doing the work!
![Page 15: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/15.jpg)
Data gathered by the Tufts Center for the Study of Drug Development (Tufts CSDD)
>90% of all clinical trials delayed due to over-ambitious timelines and difficulty with patient enrollment
Top reasons for delays in trials: Protracted budget negotiationsSlow IRB review and approvalPoor patient recruitment and retention
Estimated 20% of PIs fail to enroll a single patient and 30% under-enroll in a given trial
Between 2000 and 2005 38% of PIs who participated in clinical trials in a given year did not return in a subsequent year through 2008
Up from 26% in previous 5 years
![Page 16: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/16.jpg)
Patient Recruitment and RetentionPatient Recruitment and Retention
1999-2002 2003-2006
Percent Screened who were Randomized 75% 59%
Percent Randomized who Completed the
Study69% 48%
Screen : Complete 50% 25%
Source: Tufts CSDD
•Performance data on 57 phase II and III (across TAs) protocols provided by five pharmaceutical companies
![Page 17: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/17.jpg)
8.7%10.5%
12.1%
-7.9%
6.5%
Number of UniqueProcedures
Frequency ofProcedures
Execution Burden Number ofEligibility Criteria
Ann
ual G
row
th R
ate
Compensation per Procedure
Protocol Designs More Complex and BurdensomeProtocol Designs More Complex and Burdensome
((2000-2006)2000-2006)
Sources: Tufts CSDD; Getz et al. Assessing the Impact of Protocol Design Change on Clinical Trial Performance. American Journal of Therapeutics. 2008 15(5); 450 - 457
Represents 10,038 industry protocols; provided by Fast Track SystemsWork effort values based on Medicare’s RVU methodology
![Page 18: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/18.jpg)
Performance ‘Impact’ of protocol complexityPerformance ‘Impact’ of protocol complexity
Compared US-based pivotal trial protocols executed 1999-2002 (lower complexity) and 2003-2006 (higher complexity):
Number of CRF pages rose to an average of 180 pages vs. 55
Controlling for treatment duration, cycle times increased substantially across all measures
Enrollment rates worsenedSource: Tufts CSDD
![Page 19: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/19.jpg)
Cycle Time MetricsCycle Time Metrics
115 120
413460
129 143
714780
Protocol Ready toFPFV
Protocol Ready toDrug Available
Protocol Ready toLPLV
Protocol Ready toData Lock
1999-2002 2003-2006
12% – 20% Increase
69% - 75% Increase
Med
ian
Day
s Ela
psed
Source: Tufts CSDD
![Page 20: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/20.jpg)
![Page 21: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/21.jpg)
![Page 22: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/22.jpg)
Clinical Trial Cost EstimatesClinical Trial Cost Estimates
$0$50
$100$150$200$250$300$350$400$450
To talCo ord in ating CenterS ite Paym entsOth er
Full Cost Industry
Streamlined Industry
More Streamlined
$ In US 2007 Millions
![Page 23: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/23.jpg)
Source: Roses AD. Nature 2000;405:857-865.
Pharmacogenomics
![Page 24: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/24.jpg)
Randomized Trial of Genotype-Guided Dosing of Warfarin Therapy:Influence of Genotype on Warfarin Dose?
Genotype(N = 188)
Prevalence % Enzyme Activity
S/R Warfarin(mg/L)
Daily Doses(mg)
Clearance/LBW
(ml/min/kg)
2C9 *1/*1 64% 100% 0.45 (0.11)
5(2.5)
0.065 (0.025)
2C9 *1/*2*2/*2
21% 50-70% 0.69(0.28)
3(1.5)
0.041 (0.021)
2C9 *1/*3*2/*3 *3/*3
15% 10% 1.43(0.63)
2(1.0)
0.020 (0.011)
Herman et al, The Pharmacogenomics J 4:1-10. 2005
McClain et al, ACMG Presentation, October 30, 2006 (In Press)(From L. Lesko)
![Page 25: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/25.jpg)
Randomized Trial of Genotype-Guided Dosing of Warfarin TherapyBoxplots of distribution of warfarin dose byCYP2C9 and VKORC1 genotype
Sconce et al. Blood 2005; 106:2329
![Page 26: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/26.jpg)
-NEJM 360; 2009
![Page 27: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/27.jpg)
Cytochrome P-450 Polymorphisms and Clopidogrel Response
-NEJM 360; 2009
![Page 28: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/28.jpg)
Cytochrome P-450 Polymorphisms and Clopidogrel Response
-NEJM 360; 2009
![Page 29: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/29.jpg)
GENEVA, SWITZERLAND—World Health Organization officials expressed disappointment Monday at the group's finding that, despite the enormous efforts of doctors, rescue workers and other medical
professionals worldwide, the global death rate remains constant at 100 percent.Death, a metabolic affliction causing total shutdown of all life functions, has long been considered
humanity's number one health concern. Responsible for 100 percent of all recorded fatalities worldwide, the condition has no cure.
"I was really hoping, what with all those new radiology treatments, rescue helicopters, aerobics TV shows and what have you, that we might at least make a dent in it this year," WHO Director General Dr. Gernst Bladt said. "Unfortunately, it would appear that the death rate remains constant and total, as it
has inviolably since the dawn of time."
![Page 30: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/30.jpg)
The Good--More Research will be DoneThe Good--More Research will be Done
Broader sources of fundingBroader sources of fundingMany governments now giving tax breaks for Many governments now giving tax breaks for industry funded researchindustry funded research
Do the research where costs are lessDo the research where costs are less
Do the research where barriers to trial initiation Do the research where barriers to trial initiation are lessare less
![Page 31: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/31.jpg)
ACC/AHA Clinical Practice Guidelines
![Page 32: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/32.jpg)
19.0%
44.9%
36.3% LoE A
LoE B
LoE C
ACC/AHA Guidelines: Level of Evidence of Recommendations
![Page 33: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/33.jpg)
0%
10%
20%
30%
40%
50%
60%
70%
A B C A B C A B C A B C A B C A B CAtrial
Fibrillation (2001-2006)
Heart Failure
(2001-2006)
Stable Angina
(1999-2002)
Unstable Angina
(2000-2007)
PCI (2001-2005)
Pacemaker (1998-2002)
ACC/AHA Guidelines: More GuidelinesNo Improvement in Proportion with High Quality!
![Page 34: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/34.jpg)
The BadThe Bad
Differences in practices can be found as a Differences in practices can be found as a function of geographyfunction of geography
Differences in outcomes can be found as a Differences in outcomes can be found as a function of geographyfunction of geography
Differences in treatment effect can be found as Differences in treatment effect can be found as a function of geographya function of geography
![Page 35: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/35.jpg)
Andrzej Budaj for the GRACE Investigators
Postgraduate Medical School, Grochowski Hospital, Warsaw Poland
Current Practices in ACS Care
USA vs Rest of GRACE
![Page 36: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/36.jpg)
In-hospital ManagementAll ACS
USA Rest of GRACE
AA (%) 95 95
B-blockers (%) 88 82
ACE-I (%) 61 66
Statins (%) 65 66
B-blockers iv (%) 27 9
ARB (%) 7 5
Other lipid lowering (%) 8 3
![Page 37: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/37.jpg)
Temporal trends USA vs Rest of GRACE
4.24.8
4.04.7
4.44.9
6.35.7
2
3
4
5
6
7
8
2000 2002 2004 2006
USARest of GRACE
% Death in hospitalAll ACS
![Page 38: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/38.jpg)
9808LB11, 9808LB11, 3838
Death and/or MI at 30 Days
FemaleFemale
MaleMale
0.50.5 11 1.51.5
Placebo EptifibatideTotal n
16.88 13.896103
13.68 14.88
3357
PlaceboBetter
EptifibatideBetter
PT-E2-7PT-E2-7
![Page 39: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/39.jpg)
9808LB11, 9808LB11, 3939
Death and/or MI
FemaleFemaleMaleMale
FemaleFemaleMaleMale
FemaleFemaleMaleMale
FemaleFemaleMaleMale
0.20.2 11 55
Placebo Eptifibatide Total n16.16 12.35 249912.89 10.57 132816.03 13.03 254212.10 15.52 115420.35 20.43 81419.05 21.78 72721.43 16.39 2485.63 15.58 148
PlaceboBetter
EptifibatideBetter
NA
WE
EE
LA
PT-E2-8PT-E2-8
![Page 40: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/40.jpg)
9808LB11, 9808LB11, 4040
Timing of Angiography
0
25
50
75
100
72Hours
7Days
30Days
72Hours
7Days
30Days
72Hours
7Days
30Days
72Hours
7Days
30Days
72Hours
7Days
30Days
%
MaleFemale
Overall North America
Western Europe
Eastern Europe
Latin America
PT-C-17PT-C-17
![Page 41: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/41.jpg)
Study Undertaken by FDA Study Undertaken by FDA statisticians to evaluate statisticians to evaluate possibility of systematic possibility of systematic
regional differencesregional differences Major cardiovascular outcome Major cardiovascular outcome
studies evaluated over the last 10 studies evaluated over the last 10 yearsyears
Overall study result statistically Overall study result statistically positive, ie. demonstrated overall positive, ie. demonstrated overall effecteffect
Region never pre-specified as a Region never pre-specified as a factor to be evaluated statisticallyfactor to be evaluated statistically
16 independent studies16 independent studies
![Page 42: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/42.jpg)
difference of log-hazard ratios
Study % US
-1.5 -1.0 -0.5 0.0 0.5 1.0 1.5
31145227394451964373884974107411912313291417159016
Estimates and confidence intervals for difference between US and Non-US treatment effects for each
study
J. Lawrence
In 13 of 16 , US log hazard above 0
![Page 43: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/43.jpg)
![Page 44: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/44.jpg)
A figureFrom the label
![Page 45: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/45.jpg)
External ValidityExternal Validity
Internal ValidityInternal Validity
Goal
X
![Page 46: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/46.jpg)
Article cites numerous examples of trials, which produce Article cites numerous examples of trials, which produce parameter estimates of questionable value to Western parameter estimates of questionable value to Western European decision makers and highlights differences European decision makers and highlights differences between emerging regions and Western Europeans, which between emerging regions and Western Europeans, which suggest the two are mutually incomparable.suggest the two are mutually incomparable.
Proposed that these differences may confound study Proposed that these differences may confound study outcomes, decision-making parameter estimates and data outcomes, decision-making parameter estimates and data pertaining to the incidence of adverse drug interactionspertaining to the incidence of adverse drug interactions
Further research should be undertaken in order to explore Further research should be undertaken in order to explore the relationship between geographical variance and the relationship between geographical variance and external validity, particularly where safety data derived external validity, particularly where safety data derived from relatively drug naïve regions are assumed to pertain from relatively drug naïve regions are assumed to pertain to a maximally treated populations elsewhere in the worldto a maximally treated populations elsewhere in the world
Source: Wathal. Outsourcing Clinical Trials www.samedanltd.com
![Page 47: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/47.jpg)
Extrinsic factors such as medical practice, disease definition and Extrinsic factors such as medical practice, disease definition and study population may influence applicability of foreign data to an study population may influence applicability of foreign data to an EU settingEU setting
Global drug development doesn’t necessarily support approval of Global drug development doesn’t necessarily support approval of unrestricted indications in an EU populationunrestricted indications in an EU population
Consider and discuss possible influence of extrinsic Consider and discuss possible influence of extrinsic factors on interpretation of results and wording of factors on interpretation of results and wording of indicationsindications
In depth, prospective analysis of potential ethnic factors when In depth, prospective analysis of potential ethnic factors when conducting a clinical trial in a certain region.conducting a clinical trial in a certain region.
Depending on the outcome of analyses can be Depending on the outcome of analyses can be decided whether certain clinical trials conducted in a decided whether certain clinical trials conducted in a specific area of the world would be relevant to EU specific area of the world would be relevant to EU setting or if there are reasons to perform additional setting or if there are reasons to perform additional clinical trials within the EUclinical trials within the EU
Source: European Medicines Agency, Pre-Authorization Evaluation of Medicines for Human Use. Feb. 19, 2009
![Page 48: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/48.jpg)
Verification at time of evaluation of marketing Verification at time of evaluation of marketing authorization application that trials have been authorization application that trials have been conducted in accordance with GCP and ethical conducted in accordance with GCP and ethical standardsstandards
Greater transparency of this process and Greater transparency of this process and its outcome should be described in the its outcome should be described in the European Public Assessment Report (EPAR)European Public Assessment Report (EPAR)
Increased GCP inspection including further Increased GCP inspection including further extension of GCP policy on increasing numbers of extension of GCP policy on increasing numbers of routine inspections as part of the need for greater routine inspections as part of the need for greater supervision of the conduct and ethical standards of supervision of the conduct and ethical standards of clinical trials performed outside the EEAclinical trials performed outside the EEA
Source: European Medicines Agency, EMEA strategy paper: acceptance of clinical trials conducted in the third countries, for evaluation in Marketing Authorization Applications. Feb. 5, 2008
![Page 49: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/49.jpg)
Source: Reed SD, Drug Information Journal, 2007
![Page 50: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/50.jpg)
Source: Reed SD, Drug Information Journal, 2007
![Page 51: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/51.jpg)
Source: Reed SD, Drug Information Journal, 2007
![Page 52: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/52.jpg)
The UglyThe Ugly
Differences in reported adverse events can be Differences in reported adverse events can be found in different countriesfound in different countries
Is there a relationship between relative financial Is there a relationship between relative financial incentive and lower rates of side effects?incentive and lower rates of side effects?
Differences in adherence can be found in Differences in adherence can be found in different countriesdifferent countries
Is there a relationship between lack of access to Is there a relationship between lack of access to health care outside of the trial and adherence?health care outside of the trial and adherence?
![Page 53: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/53.jpg)
The UglyThe Ugly
Non-Non-AdherencAdherencee
WithdrawaWithdrawal:AE’sl:AE’s
WithdrawaWithdrawal: Subject l: Subject preferencepreference
Withdrew Withdrew ConsentConsent
UKUK 39.7%39.7% 12%12% 17%17% 5555USUS 35.5%35.5% 7%7% 16%16% 166166Poland Poland 14.8%14.8% 2%2% 9%9% 22ChinaChina 6.1%6.1% 5%5% 5%5% 11ArgentinaArgentina 13.6%13.6% 2%2% 8%8% 11
![Page 54: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/54.jpg)
The ObsceneThe Obscene
When the per patient reimbursement exceeds When the per patient reimbursement exceeds reasonable levels, the human experimentation reasonable levels, the human experimentation entrepreneurs will be tempted entrepreneurs will be tempted
When the FDA cannot inspect, the cheaters will When the FDA cannot inspect, the cheaters will figure out how to get the data looking real figure out how to get the data looking real good!good!
![Page 55: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/55.jpg)
Source: http://www.tampabay.com/news/business/article934677.ece
![Page 56: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/56.jpg)
Source: http://www.tampabay.com/news/business/article934633.ece
![Page 57: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/57.jpg)
Source: http://www.tampabay.com/opinion/essays/article934654.ece
![Page 58: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/58.jpg)
Ethical Concerns in clinical trials in India: an investigation
• Lapatinib, GlaxoSmithKline– The majority of breast cancer patients in India cannot
afford proper treatment. This trial required seriously ill patients who had not received treatment for their condition.
– Their economic vulnerability forces patients in India to take part in trials in order to get access to treatment and to disregard the potential risks that participating in clinical trials entails. By carrying out this clinical trial in India GlaxoSmithKline (GSK) took advantage of the vulnerable position of breast cancer patients.
Source: Srinivasan S, et al. Ethical concerns in clinical trials in India: an investigation. Center for Studies in Ethics and Rights, Mumbai, India. Feb. 2009
![Page 59: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/59.jpg)
• Risperidone, Johnson & Johnson– Patients in trial were suffering from an acute
attack of a psychiatric condition that would have caused them much distress.
– They were harmed because they were taken off all treatment before they were put on either the active drug or a placebo.
– Those on the placebo were also harmed because they were deprived of an effective treatment
Ethical Concerns in clinical trials in India: an investigation
Source: Srinivasan S, et al. Ethical concerns in clinical trials in India: an investigation. Center for Studies in Ethics and Rights, Mumbai, India. Feb. 2009
![Page 60: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/60.jpg)
• Quetiapine fumurate extended release, AstraZeneca– These two placebo-controlled trials of
quetiapine were conducted on patients with schizophrenia. An immediate release formulation of the drug had already been approved and these trials were of an extended release version of the drug.
– A patient in one of the quetiapine trials committed suicide after 173 days of being on placebo.
Ethical Concerns in clinical trials in India: an investigation
Source: Srinivasan S, et al. Ethical concerns in clinical trials in India: an investigation. Center for Studies in Ethics and Rights, Mumbai, India. Feb. 2009
![Page 61: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/61.jpg)
![Page 62: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/62.jpg)
Factors Pulling Research Offshore
• Cost: cost per patient may be 1/10 the cost in the US (Garnier, JP).
• Availability: untreated or under-treated patients may speed recruitment of patients to clinical trials reducing the time costs of research.
• Regulations: local processes may be more variable (and potentially less restrictive) than in the US.
Source: Garnier JP. Rebuilding the R&D engine in big pharmacy. Harv Bus Rev 2008;86:68-76.
![Page 63: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/63.jpg)
Factors Pushing Research Offshore
• Costs (Clinical Care)• Costs (Administrative)
• Systems that developed to govern single site studies are inefficient in oversight of multicenter, multinational studies
• IRB (redundant site level process)• Contracting (redundant site level process)• Compliance (research as a potential criminal
issue)
![Page 64: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/64.jpg)
Administrative Barriers
Source: Dilts, DM et al. Journal of Clinical Oncology Oct. 2006
![Page 65: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/65.jpg)
CommentsEvent Time
IRB Approval Timeline for a Focus Group discussing Health Insurance with Latinos
Oct 2007
Feb 2008
Apr 2008
Oct 2008
Jan 2009
Aug 2007
Aug-Sep 2007
May-Sep 2008
Rewritten study submitted to IRB
Continued negotiations between local cultural center and IRB
Local cultural center requests major changes to study
Initial study approved by IRB
Study rewritten and submitted as expedited
Discussions with IRB about rejection of exempt status
Study Submitted to IRB as Exempt
IRB requested additional changes
Incorporate relevant cultural concerns in initial study design
IRB requested extensive changes
Focus groups may not qualify for IRB exempt status
IRB rejected exempt status
Final Study Approved
![Page 66: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/66.jpg)
Contracting for Clinical Research
“…the system would be better served if there were universally accepted
contractual language …Such language would help safeguard the
integrity of the research process.”
-JEFFREY M. DRAZENEditor-in-Chief, New England Journal of Medicine
Source: Drazen, JM. NEJM Oct. 24, 2002
![Page 67: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/67.jpg)
(1) I am familiar with, and will comply with, applicable federal regulations and guidance for the protection of human subjects: HHS regulations at 45 FR 46 and associated guidance; FDA regulations at 21 CFR Parts 50, 54, 56, 312, 314, 601, 812, and 814 and associated guidance; the HIPAA privacy regulations at 45 CFR Parts 160 and 164 and associated guidance; the DUHS Federal-Wide Assurance; and relevant institutional policies and procedures for the protection of human research subjects.
Source: DUHS Principal Investigator Agreement form. Version 6/25/08
![Page 68: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/68.jpg)
Source: Glickman, SW et al. NEJM 2009.
![Page 69: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/69.jpg)
Selection of Patients in Multinational Trials
• Problem: Research in communities that are not intended to be major markets for the products under testing can be ethically problematic
• Solutions– Sponsors should describe how trial populations match
intended markets– Create target enrollment according to region on the basis
of intended use of product, similar to target enrollment of women and minorities
Source: Glickman, SW et al. NEJM 2009.
![Page 70: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/70.jpg)
Transparency of Clinical Trial Results in Developing Countries
• Problem: Protection of publication rights and access to trial data for investigators is necessary to preserve the integrity of research
• Solutions– Publish all data regardless of research location, and
reinforce requirements according to FDA Amendments Act of 2007
– Preserve publication rights globally through legal agreements at onset of trial
– Create trial leadership that incorporates representatives of countries involved in study
Source: Glickman, SW et al. NEJM 2009.
![Page 71: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/71.jpg)
Regulatory Oversight of International Clinical Research
• Problem: Regulatory agencies have little information on trials conducted outside their countries
• Solutions– Mechanism for sharing regulatory oversight among
government agencies worldwide– Public registry of IRBs and inventory of country-specific
provisions for ethical oversight– Comprehensive study of the globalization of clinical
research by IOM or WHO– Central statistical monitoring system to find unusual data
patterns suspicious for fraud
Source: Glickman, SW et al. NEJM 2009.
![Page 72: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/72.jpg)
Training and Experience of Clinical Investigators
• Problem: Investigators in developing countries are typically less experienced than investigators in developed countries
• Solutions– Formal training programs for clinical research for
investigators in developing countries to expand global clinical research leadership capacity and improve collaboration worldwide
– Mechanism for tracking investigators who are trained to conduct clinical trials and those who have been prohibited from conducting trials
Source: Glickman, SW et al. NEJM 2009.
![Page 73: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/73.jpg)
Genomic Information in Drug Development
• Problem: Lack of pharmacogenomic data for subjects limits confidence in generalizability of results
• Solutions– Expand FDA Voluntary Genomic Data Submissions
program to international regulatory agencies– Develop global data warehousing and data analysis
capabilities
Source: Glickman, SW et al. NEJM 2009.
![Page 74: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/74.jpg)
IRB Quality and Inefficiency
• Problem: Redundancy in review process may harm patient safety by requiring diversion of effort to unnecessary procedures and practices
• Solutions– Greater use of centralized IRBs (eg, Central IRB
Initiative, European Union Clinical Trials Directive)– Mutual acceptance of proposal review in consortia (eg,
Biomedical Research Alliance of New York)– Streamlined best practices to reduce unnecessary
work for investigators (eg, Clinical Trials Transformation Initiative)
Source: Glickman, SW et al. NEJM 2009.
![Page 75: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/75.jpg)
Payment Compliance• Problem: Increased costs and delays in payment
for research subjects divert financial support from research to administration and make research less attractive to investigators because of risk of criminal penalties
• Solutions– Establish nonpunitive mechanism for reconciliation of
payment– Expand mechanisms to pay for usual care services (eg,
within Medicare and Medicaid)
Source: Glickman, SW et al. NEJM 2009.
![Page 76: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/76.jpg)
Commercial Contracts• Problem: Variety of contracting practices
brings complexity and delays to research• Solutions
– Adopt standard contract language for clinical research agreements
Source: Glickman, SW et al. NEJM 2009.
![Page 77: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/77.jpg)
Confidentiality Agreements inCommercial Contracts
• Problem: Confidentiality agreements reduce the transparency and efficiency of clinical research
• Solutions– Adopt standard confidentiality language for clinical
research agreements
Source: Glickman, SW et al. NEJM 2009.
![Page 78: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/78.jpg)
A collaborative effort to find solutions In light of these issues the U.S. FDA’s Office of
Critical Path Programs and Duke University joined together as founding members of a public-private partnership:
The Clinical Trials Transformation Initiative (CTTI)
All stakeholders are involved in this initiative including government, industry, academia, patient advocates, clinical investigators, professional societies, and others
![Page 79: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/79.jpg)
Mission
To identify practices that through broad adoption will increase the quality and efficiency of clinical trials
![Page 80: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/80.jpg)
Scope
CTTI will conduct projects in support of its mission to identify practices that will increase the quality and efficiency of clinical trials
“Quality” - the ability to effectively answer the intended question about the benefits and risks of a medical product (therapeutic or diagnostic) or procedure, while assuring protection of human subjects
![Page 81: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/81.jpg)
Scope (continued)
CTTI will generate evidence about how to improve the design and execution of clinical trials
Projects about design will address principles generally applicable to clinical trials to assure that they are fit to accomplish their intended purpose.
![Page 82: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/82.jpg)
Scope (continued)
While CTTI focuses on clinical trials, it may study other types of clinical research (e.g., registries) that can provide data to regulatory agencies.
Although CTTI will concentrate initially on the design and conduct of clinical trials in the United States, it seeks to identify practice improvements that can be applied internationally.
![Page 83: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/83.jpg)
Executive Committee FDA: (Rachel Behrman, OC, Co-chair; Bob Temple,
CDER, Bram Zuckerman, CDRH) Duke: (Rob Califf, Co-chair) NIH liaison: (Amy Patterson) Industry: (Glenn Gormley, Jay Siegel, Susan Alpert,
Alberto Grignolo) Academia: (David DeMets) Patient representative: (Nancy Roach) At-large representative: (Ken Getz) Non-US regulatory liaison: (Hans-Georg Eichler, EMEA) Steering Committee co-chairs, ex officio (James
Ferguson, Briggs Morrison)
![Page 84: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/84.jpg)
Member Organizations Category # organizationsPharmaceutical companies 7Clinical research organizations 7Academic institutions 7Professional societies 7Device companies 6Biotechnology companies 5Government 4 (FDA, CMS, NIH, OHRP)Clinical investigator groups 3Trade organizations 3Patient representatives 2 (TBD)Private equity firm 1Regulatory law firm 1
*Began recruiting members May 2008
![Page 85: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/85.jpg)
Projects Priority areas defined by Executive Committee:
Design principlesData quality and quantity (including monitoring)Study start-upAdverse event reporting
Information about the process for submission, review, and approval of projects available at CTTI Web site:
www.trialstransformation.org/projects
![Page 86: Economics of Oncology Drug Development](https://reader035.fdocuments.in/reader035/viewer/2022062600/58a30e361a28ab863a8bbd27/html5/thumbnails/86.jpg)
Life Expectancy at Birth: Developed and Developing Countries, 1955-2002
Source: World Health Report 2003